221 related articles for article (PubMed ID: 22272488)
1. Iatrogenic autoimmune progesterone dermatitis caused by 17alpha-hydroxyprogesterone caproate for preterm labor prevention.
Bandino JP; Thoppil J; Kennedy JS; Hivnor CM
Cutis; 2011 Nov; 88(5):241-3. PubMed ID: 22272488
[TBL] [Abstract][Full Text] [Related]
2. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
O'Brien JM; Lewis DF
Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
[TBL] [Abstract][Full Text] [Related]
3. The rebirth of progesterone in the prevention of preterm labor.
Schmouder VM; Prescott GM; Franco A; Fan-Havard P
Ann Pharmacother; 2013 Apr; 47(4):527-36. PubMed ID: 23535817
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological use of progesterone and 17-alpha-hydroxyprogesterone caproate in the prevention of preterm delivery.
Facchinetti F; Vaccaro V
Minerva Ginecol; 2009 Oct; 61(5):401-9. PubMed ID: 19749671
[TBL] [Abstract][Full Text] [Related]
5. Does progesterone treatment influence risk factors for recurrent preterm delivery?
Meis PJ; Klebanoff M; Dombrowski MP; Sibai BM; Leindecker S; Moawad AH; Northen A; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Miodovnik M; Leveno KJ; Conway D; Wapner RJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S
Obstet Gynecol; 2005 Sep; 106(3):557-61. PubMed ID: 16135587
[TBL] [Abstract][Full Text] [Related]
6. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial.
Lim AC; Bloemenkamp KW; Boer K; Duvekot JJ; Erwich JJ; Hasaart TH; Hummel P; Mol BW; Offermans JP; van Oirschot CM; Santema JG; Scheepers HC; Schöls WA; Vandenbussche FP; Wouters MG; Bruinse HW;
BMC Pregnancy Childbirth; 2007 Jun; 7():7. PubMed ID: 17578562
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery.
Saghafi N; Khadem N; Mohajeri T; Shakeri MT
J Obstet Gynaecol Res; 2011 Oct; 37(10):1342-5. PubMed ID: 21564406
[TBL] [Abstract][Full Text] [Related]
8. What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?
Hall NR
Obstet Gynecol Clin North Am; 2011 Jun; 38(2):235-46, ix-x. PubMed ID: 21575799
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of randomized controlled trials comparing 17α-hydroxyprogesterone caproate and vaginal progesterone for the prevention of recurrent spontaneous preterm delivery.
Oler E; Eke AC; Hesson A
Int J Gynaecol Obstet; 2017 Jul; 138(1):12-16. PubMed ID: 28369874
[TBL] [Abstract][Full Text] [Related]
10. The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.
Bustos ML; Caritis SN; Jablonski KA; Reddy UM; Sorokin Y; Manuck T; Varner MW; Wapner RJ; Iams JD; Carpenter MW; Peaceman AM; Mercer BM; Sciscione A; Rouse DJ; Ramin SM;
Am J Obstet Gynecol; 2017 Sep; 217(3):369.e1-369.e9. PubMed ID: 28522317
[TBL] [Abstract][Full Text] [Related]
11. Using 17 α-hydroxyprogesterone caproate to impact rates of recurrent preterm delivery in clinical practice.
Rebarber A; Fox NS; Klauser CK; Istwan NB; Rhea DJ; Stanziano GJ; Saltzman DH
J Matern Fetal Neonatal Med; 2010 Oct; 23(10):1139-42. PubMed ID: 20170407
[TBL] [Abstract][Full Text] [Related]
12. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.
Meis PJ; Klebanoff M; Thom E; Dombrowski MP; Sibai B; Moawad AH; Spong CY; Hauth JC; Miodovnik M; Varner MW; Leveno KJ; Caritis SN; Iams JD; Wapner RJ; Conway D; O'Sullivan MJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S;
N Engl J Med; 2003 Jun; 348(24):2379-85. PubMed ID: 12802023
[TBL] [Abstract][Full Text] [Related]
13. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
Odibo AO; Stamilio DM; Macones GA; Polsky D
Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
[TBL] [Abstract][Full Text] [Related]
14. Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection.
Mainiero AD; Rouse DJ; Lopes V; Hughes BL
Obstet Gynecol; 2015 Jul; 126(1):103-8. PubMed ID: 26241262
[TBL] [Abstract][Full Text] [Related]
15. 17 hydroxyprogesterone for the prevention of preterm delivery.
Meis PJ;
Obstet Gynecol; 2005 May; 105(5 Pt 1):1128-35. PubMed ID: 15863556
[TBL] [Abstract][Full Text] [Related]
16. The safety of progesterone and 17-hydroxyprogesterone caproate administration for the prevention of preterm birth: an evidence-based assessment.
O'Brien JM
Am J Perinatol; 2012 Oct; 29(9):665-72. PubMed ID: 22773279
[TBL] [Abstract][Full Text] [Related]
17. Single dose 17 alpha-hydroxyprogesterone caproate in preterm labor: a randomized trial.
Tan PC; King AS; Vallikkannu N; Omar SZ
Arch Gynecol Obstet; 2012 Mar; 285(3):585-90. PubMed ID: 21796421
[TBL] [Abstract][Full Text] [Related]
18. Progesterone does not prevent preterm births in women with twins.
Briery CM; Veillon EW; Klauser CK; Martin RW; Chauhan SP; Magann EF; Morrison JC
South Med J; 2009 Sep; 102(9):900-4. PubMed ID: 19668021
[TBL] [Abstract][Full Text] [Related]
19. ACOG Committee Opinion. Use of progesterone to reduce preterm birth.
American College of Obstetricians and Gynecologists
Obstet Gynecol; 2003 Nov; 102(5 Pt 1):1115-6. PubMed ID: 14672496
[TBL] [Abstract][Full Text] [Related]
20. The association between 17-hydroxyprogesterone caproate use and postpartum hemorrhage.
Miller ES; Sakowicz A; Roy A; Liu LY; Yee LM
Am J Obstet Gynecol MFM; 2019 May; 1(2):144-147. PubMed ID: 32914089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
